Literature DB >> 14707728

Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins.

Hidenori Miyamoto1, Tatsuya Murakami, Kunihiro Tsuchida, Hiromu Sugino, Hidenori Miyake, Seiki Tashiro.   

Abstract

INTRODUCTION: Pancreatic cancer is one of the major causes of cancer-related deaths in industrialized countries. It is known that pancreatic cancer is resistant to chemotherapy and that cancer cells are surrounded by extracellular matrix (ECM) proteins including collagen I, collagen IV, fibronectin, and laminin. AIMS: To examine the role of ECM proteins in acquired resistance to anticancer drugs and proliferation regulation in pancreatic cancers. METHODOLOGY AND
RESULTS: We used an in vitro model of ECM-induced chemoresistance and cell proliferation of cancer cell lines (MIA PaCa-2, PANC-1, and Capan-1) with 3 different malignancy grades and found that resistance to cytotoxic drugs and proliferation regulation was dependent on ECM proteins. Pancreatic cancer cell lines, especially MIA PaCa-2 cells, adhering to any of the ECM proteins showed decreased cytotoxicity of anticancer drugs, except for gemcitabine. PANC-1 and Capan-1 cells adhering to fibronectin, collagen I, and collagen IV proliferated more than the controls.
CONCLUSION: ECM proteins have important roles in acquired resistance to anticancer drugs and cell proliferation regulation of pancreatic cancer cells. Therefore, the expression of ECM proteins in pancreatic cancer specimens could provide valuable information to aid anticancer drug cytotoxicity, and gemcitabine would be useful for treatment of patients with pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14707728     DOI: 10.1097/00006676-200401000-00006

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  104 in total

Review 1.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

Review 2.  The role of radiotherapy in locally advanced pancreatic carcinoma.

Authors:  Ruchika Gutt; Stanley L Liauw; Ralph R Weichselbaum
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-07-13       Impact factor: 46.802

3.  Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.

Authors:  Mohammad Aslam Khan; Sanjeev Kumar Srivastava; Haseeb Zubair; Girijesh Kumar Patel; Sumit Arora; Moh'd Khushman; James Elliot Carter; Gregory Stephen Gorman; Seema Singh; Ajay Pratap Singh
Journal:  J Biol Chem       Date:  2020-05-01       Impact factor: 5.157

Review 4.  [Proteome analysis--basis for individualized pancreatic carcinoma therapy?].

Authors:  J M Löhr; R Faissner; P Findeisen; M Neumaier
Journal:  Internist (Berl)       Date:  2006-06       Impact factor: 0.743

5.  Type I collagen and divalent cation shifts disrupt cell-cell adhesion, increase migration, and decrease PTHrP, IL-6, and IL-8 expression in pancreatic cancer cells.

Authors:  John J Grzesiak; Kathy C Smith; Cheryl Chalberg; Douglas W Burton; Leonard J Deftos; Michael Bouvet
Journal:  Int J Gastrointest Cancer       Date:  2005

6.  Clinical significance of serum COL6A3 in pancreatic ductal adenocarcinoma.

Authors:  Christopher Y Kang; Jonathan Wang; Dierdre Axell-House; Pranay Soni; Mon-Li Chu; Galina Chipitsyna; Konrad Sarosiek; Jocelyn Sendecki; Terry Hyslop; Mazhar Al-Zoubi; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2013-09-04       Impact factor: 3.452

Review 7.  [Pharmacological characterization of head and neck cancer in ex-vivo tests].

Authors:  G Wichmann; A Dietz
Journal:  HNO       Date:  2011-09       Impact factor: 1.284

Review 8.  Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response.

Authors:  Matthew David Hale; Jeremy David Hayden; Heike Irmgard Grabsch
Journal:  Cell Oncol (Dordr)       Date:  2013-03-14       Impact factor: 6.730

9.  Assay-based response evaluation in head and neck oncology: requirements for better decision making.

Authors:  Andreas Dietz; Andreas Boehm; Iris-Susanne Horn; Pierre Kruber; Ingo Bechmann; Wojciech Golusinski; Dietger Niederwieser; Ralph Dollner; Torsten W Remmerbach; Christian Wittekind; Stephan Dietzsch; Guido Hildebrandt; Gunnar Wichmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-06       Impact factor: 2.503

Review 10.  Targeting the tumour stroma to increase efficacy of chemo- and radiotherapy.

Authors:  G Chometon; V Jendrossek
Journal:  Clin Transl Oncol       Date:  2009-02       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.